Alport Syndrome Epidemiology Forecast

Alport Syndrome Insights and Trends

• According to DelveInsight’s analysis, Alport syndrome the total diagnosed prevalent cases was found to be around 51,900 in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
• It is a lifelong condition with an estimated prevalence of ~1 in 5,000–10,000 individuals, though the true burden is likely underestimated due to underdiagnosis and recognition of a broader “Alport spectrum”, encompassing both severe and milder phenotypes.
• The disease exhibits heterogeneous inheritance patterns, predominantly X-linked (~80%), with males typically experiencing earlier onset and faster progression to end-stage renal disease (ESRD), while females and autosomal forms show variable but still clinically significant disease progression.
• Individuals with Alport syndrome may experience symptoms for an extended period before receiving a diagnosis. The condition is frequently without symptoms until later stages, and having a family history of Alport syndrome serves as a crucial signal for undergoing screening.
• Diagnosis remains challenging and is frequently delayed due to phenotypic variability and overlap with other renal conditions (e.g., IgA nephropathy), with genetic testing now considered the gold standard but still not universally implemented in routine clinical practice.
• The underlying pathophysiology involves defective type IV collagen assembly, resulting in progressive glomerular basement membrane thinning, splitting, and fibrosis, ultimately driving chronic kidney disease progression and systemic manifestations.

Alport syndrome Epidemiology Forecast in the 7MM

• 2025 Diagnosed Prevalent Cases of Alport Syndrome: ~51,900
• 2036 Projected Diagnosed Prevalent Cases of Alport Syndrome: ~XXX
• Alport Syndrome Growth Rate (2026–2036): ~2.0% CAGR

DelveInsight's ‘Alport Syndrome – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the alport syndrome, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Alport Syndrome Understanding and Diagnostic Algorithm

Alport Syndrome Overview and Diagnosis

Alport syndrome is a hereditary disorder caused by mutations in type IV collagen genes (COL4A3, COL4A4, COL4A5), affecting basement membranes of the kidneys, ears, and eyes. It presents with early hematuria and progressive kidney dysfunction that can lead to renal failure, often accompanied by hearing loss and ocular abnormalities. The disease occurs in X-linked, autosomal recessive, and autosomal dominant forms, with X-linked being the most common and severe in males. Diagnosis relies on clinical features, family history, biopsy findings, and increasingly genetic testing. There is no curative treatment; management focuses on slowing disease progression using supportive therapies, though many patients eventually require dialysis or kidney transplantation.

The diagnostic approach to Alport syndrome integrates clinical suspicion, laboratory testing, and advanced genetic analysis. It is typically suspected in individuals with persistent hematuria, family history of kidney disease, early hearing loss, or unexplained renal impairment. Initial evaluation includes urine and blood tests to assess hematuria, proteinuria, and kidney function, though these findings are not disease-specific. Kidney biopsy can provide supportive evidence through structural and collagen abnormalities, while skin biopsy may aid in select cases. However, genetic testing has become the gold standard, enabling definitive identification of mutations in COL4A3, COL4A4, and COL4A5 genes and determination of inheritance patterns. Complementary assessments such as audiometry and ophthalmologic evaluation further support diagnosis and disease monitoring.

Further details are provided in the report.

Alport Syndrome Epidemiology

Key Findings from Alport Syndrome Epidemiological Analysis and Forecast

Real-world evidence suggests that Alport syndrome remains underdiagnosed and underreported in routine clinical practice, particularly in patients with mild hematuria or slowly progressive disease who may not undergo timely genetic testing or specialist evaluation. Consequently, the true prevalence and disease burden of Alport syndrome are likely higher than currently reported, especially compared with data from clinical studies and specialized registries.

• The United States accounted for the highest prevalent cases; ~55% of total 7MM Alport syndrome cases in 2025.
• The total diagnosed prevalent cases of Alport syndrome in the 7MM were ~51,900 cases in 2025 and are projected to rise by 2036.
• In 2025, among type-specific diagnosed prevalent cases of Alport syndrome, X-linked Alport syndrome (XLAS) accounted for the highest proportion of cases; ~25,300, followed by Autosomal Dominant Alport syndrome (ADAS) and Autosomal Recessive Alport syndrome (ARAS), while digenic and other rare forms represented the smallest share.
• In the EU4 and the UK, age-specific diagnosed prevalent cases of Alport syndrome in 2025 were estimated to be lower in individuals under 20 years and higher in those aged 20 years and above (~65%).The higher proportion in adults primarily reflects delayed recognition of milder and slowly progressive disease forms, while pediatric cases are more frequently identified through earlier clinical presentation and family-based evaluation.
• In 2025, in the United States, mutation-specific diagnosed prevalent cases of Alport syndrome were in the highest in the splice site mutation and frame shift mutation segment with ~6,700 cases while nonsense mutations accounted for the lowest number of cases.

Scope of the Report

• The report covers a segment of an executive summary, a descriptive overview of Alport syndrome, explaining its causes, signs and symptoms, and pathogenesis.
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.

Report Insights

• Alport Syndrome Patient Population Forecast

Report Key Strengths

• Epidemiology-based (epi-based) Bottom-up Forecasting
• 11-year Forecast
• Patient Burden Trends (by geography)

FAQs

• What are the disease risks, burdens, and unmet needs of Alport syndrome? What will be the growth opportunities across the 7MM concerning the patient population with Alport syndrome?
• What is the historical and forecasted Alport syndrome patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?

Reasons to Buy

• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.